Junqiang Lv
Impact in
- Rehabilitation top 10%
- Exercise and Physiological Responses
- Endocrinology top 10%
- Escherichia coli research studies
Papers in
-
- Histone Deacetylase Inhibitors Research 3
- Ubiquitin and proteasome pathways 2
- Gut microbiota and health 2
- Oncology 9
- Peptidase Inhibition and Analysis 5
- Cancer-related Molecular Pathways 2
- Co-authors
- Zhi Yao (14 shared papers)Quan Wang (10 shared papers)Rong Lu (8 shared papers)Zhi‐Song Zhang (6 shared papers)Lijuan Chen (2 shared papers)Huali Zhang (2 shared papers)Lı Wang (1 shared paper)Xiaolei Li (2 shared papers)
- Journals
- Anti-Cancer Drugs (3 papers)Frontiers in Immunology (2 papers)Cell Reports (2 papers)Peptides (2 papers)Frontiers in Pharmacology (1 paper)
- Partner nations
- ChinaUnited StatesPortugal
In The Last Decade
Junqiang Lv
28 papers receiving 518 citations
Peers
Comparison fields: 5 of 85
- Rehabilitation 49
- Endocrinology 32
- Biological Psychiatry 12
- Molecular Biology 244
- Complementary and alternative medicine 26
Countries citing papers authored by Junqiang Lv
This map shows the geographic impact of Junqiang Lv's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Junqiang Lv with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Junqiang Lv more than expected).
Fields of papers citing papers by Junqiang Lv
This network shows the impact of papers produced by Junqiang Lv. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Junqiang Lv. The network helps show where Junqiang Lv may publish in the future.
Co-authors
The 25 scholars most cited alongside Junqiang Lv, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 29 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2008 | 122 | |
| 2 | 2023 | 68 | |
| 3 | 2017 | 41 | |
| 4 | 2019 | 37 | |
| 5 | 2020 | 36 | |
| 6 | 2022 | 34 | |
| 7 | 2020 | 26 | |
| 8 | 2022 | 21 | |
| 9 | 2018 | 21 | |
| 10 | 2010 | 16 | |
| 11 | 2021 | 15 | |
| 12 | 2018 | 15 | |
| 13 | 2013 | 13 | |
| 14 | 2024 | 13 | |
| 15 | 2022 | 10 | |
| 16 | Herbal formula of Bushen Jianpi combined with sorafenib inhibits hepatocellular carcinoma growth by promoting cell apoptosis and blocking the cell cycle. | 2021 | 7 |
| 17 | 2024 | 7 | |
| 18 | 2011 | 4 | |
| 19 | 2025 | 3 | |
| 20 | 2007 | 3 |
About Junqiang Lv
Junqiang Lv is a scholar working on Molecular Biology, Oncology, Epidemiology, Immunology and Cancer Research, having authored 29 papers that have together received 528 indexed citations. Recurring topics across this work include Peptidase Inhibition and Analysis (5 papers), Urinary Tract Infections Management (3 papers), Histone Deacetylase Inhibitors Research (3 papers), Escherichia coli research studies (3 papers), Cancer, Hypoxia, and Metabolism (3 papers), Ubiquitin and proteasome pathways (2 papers), Cancer-related Molecular Pathways (2 papers) and Gut microbiota and health (2 papers). The work is most often cited by research in Rehabilitation (49 citations), Endocrinology (32 citations), Biological Psychiatry (12 citations), Molecular Biology (244 citations) and Complementary and alternative medicine (26 citations). Junqiang Lv has collaborated with scholars based in China, United States and Portugal. Frequent co-authors include Zhi Yao, Quan Wang, Rong Lu, Zhi‐Song Zhang, Lijuan Chen, Huali Zhang, Lı Wang, Xiaolei Li, Yanjiao Zhou and Rui Ma. Their work appears in journals such as Anti-Cancer Drugs, Frontiers in Immunology, Cell Reports, Peptides and Frontiers in Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.